Medication costs to private insurers of diversion of medications for attention-deficit hyperactivity disorder

PharmacoEconomics

Volumn 29, Issue 7, 2011, Pages 621-635

  Aldridge, Arnie P ^a   Kroutil, Larry A ^a   Cowell, Alexander J ^a   Reeves, Daniel B ^a   Van Brunt, David L ^b  

^a RTI INTERNATIONAL   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; ATOMOXETINE; DEXMETHYLPHENIDATE; METHYLPHENIDATE;

ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; DRUG COST; FEMALE; HEALTH SURVEY; HUMAN; INTERNET; INTERVIEW; MALE; PREVALENCE; PRIORITY JOURNAL; PRIVATE HEALTH INSURANCE; SENSITIVITY ANALYSIS; UNITED STATES;

ADOLESCENT; ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CRIME; CROSS-SECTIONAL STUDIES; DATA COLLECTION; DRUG COSTS; FEMALE; HEALTH CARE COSTS; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; INTERNET; MALE; MIDDLE AGED; PREVALENCE; SEX FACTORS; SUBSTANCE-RELATED DISORDERS; UNITED STATES; YOUNG ADULT;

EID: 79959280722     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11584590-000000000-00000     Document Type: Article

References (39)

1. Stockl KM, Hughes TE, Jarrar MA, et al. Physician perceptions of the use of medications for attention deficit hyperactivity disorder. J Manag Care Pharm 2003 Sep-Oct; 9 (5): 416-23
2. Faraone SV, Wilens TE. Effect of stimulant medications for attention-deficit/hyperactivity disorder on later substance use and the potential for stimulant misuse, abuse, and diversion. J Clin Psychiatry 2007; 68 Suppl. 11: 15-22 (Pubitemid 47606857)
3. Castle L, Aubert RE, Verbrugge RR, et al. Trends in medication treatment for ADHD. J Atten Disord 2007 May; 10 (4): 335-42
4. Robison LM, Sclar DA, Skaer TL, et al. National trends in the prevalence of attention-deficit/hyperactivity disorder and the prescribing of methylphenidate among school-age children: 1990-1995. Clin Pediatr (Phila) 1999 Apr; 38 (4): 209-17 (Pubitemid 29186373)
5. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994
6. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 2006 Apr; 163 (4): 716-23 (Pubitemid 44464584)
7. Goldman LS, Genel M, Bezman RJ, et al. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association. JAMA 1998 Apr 8; 279 (14): 1100-7 (Pubitemid 28177819)
8. Zamiska N. Pressed to do well on admissions tests, students take drugs. Wall Street J 2004 Nov 8; A1
9. Poulin C. Medical and nonmedical stimulant use among adolescents: from sanctioned to unsanctioned use. CMAJ 2001 Oct 16; 165 (8): 1039-44 (Pubitemid 32964866)
10. Poulin C. From attention-deficit/hyperactivity disorder to medical stimulant use to the diversion of prescribed stimulants to non-medical stimulant use: connecting the dots. Addiction 2007 May; 102 (5): 740-51 (Pubitemid 46633355)
11. Goldsworthy RC, Mayhorn CB. Prescription medication sharing among adolescents: prevalence, risks, and outcomes. J Adolesc Health 2009 Dec; 45 (6): 634-7
12. Goldsworthy RC, Schwartz NC,Mayhorn CB. Beyond abuse and exposure: framing the impact of prescription-medication sharing. Am J Public Health 2008 Jun; 98 (6): 1115-21 (Pubitemid 351793393)
13. Wilens TE, Gignac M, Swezey A, et al. Characteristics of adolescents and young adults with ADHD who divert or misuse their prescribed medications. J Am Acad Child Adolesc Psychiatry 2006 Apr; 45 (4): 408-14 (Pubitemid 43675545)
14. Birnbaum HG, White AG, Reynolds JL, et al. Estimated costs of prescription opioid analgesic abuse in the United States in 2001: a societal perspective. Clin J Pain 2006 Oct; 22 (8): 667-76 (Pubitemid 44434948)
15. White AG, Birnbaum HG, Mareva MN, et al. Direct costs of opioid abuse in an insured population in the United States. J Manag Care Pharm 2005 Jul-Aug; 11 (6): 469-79
16. White AG, Birnbaum HG, Rothman DB, et al. Development of a budget-impact model to quantify potential cost savings from prescription opioids designed to deter abuse or ease of extraction. Appl Health Econ Health Policy 2009; 7 (1): 61-70
17. Novak SP, Kroutil LA, Williams RL, et al. The nonmedical use of prescription ADHD medications: results from a national Internet panel. Subst Abuse Treat Prev Policy 2007 Oct; 2: 32
18. Office of Applied Studies (OAS). Results from the 2008 National Survey on Drug Use and Health: detailed tables. Rockville (MD): Substance Abuse and Mental Health Services Administration, 2009
19. Office of Applied Studies (OAS). The NSDUH report: nonmedical use of Adderall- among full-time college students. Rockville (MD): Substance Abuse and Mental Health Services Administration, 2009 Apr
20. DeNavas-Walt C, Proctor BD, Smith JC. Income, poverty, and health insurance coverage in the United States: 2008 (current population reports). Washington, DC: US Bureau of the Census, 2009: 60-236
21. Turner CF, Ku L, Rogers SM, et al. Adolescent sexual behavior, drug use, and violence: increased reporting with computer survey technology. Science 1998; 280: 867-73 (Pubitemid 28215590)
22. McCabe SE.Comparison of web andmail surveys in collecting illicit drug use data: a randomized experiment. J Drug Educ 2004; 34 (1): 61-72 (Pubitemid 39187060)
23. West R, Gilsenan A, Coste F, et al. The ATTEMPT cohort: a multi-national longitudinal study of predictors, patterns and consequences of smoking cessation: introduction and evaluation of internet recruitment and data collection methods. Addiction 2006 Sep; 101 (9): 1352-61 (Pubitemid 44199528)
24. Durell TM, Kroutil LA, Crits-Christoph P, et al. Prevalence of nonmedical methamphetamine use in the United States. Subst Abuse Treat Prev Policy 2008 Jul 25; 3: 19
25. Daughton JM, Kratochvil CJ. Review of ADHD pharmacotherapies: advantages, disadvantages, and clinical pearls. J Am Acad Child Adolesc Psychiatry 2009; 48 (3): 240-8
26. Kraman P. Prescription drug diversion. Lexington (KY): The Council of State Governments, 2004
27. Thomson Reuters. REDBOOK-.AnnArbor (MI): Thomson Reuters, 2009 [online]. Available from URL: http://www.micromedex.com/products/redbook/ [Accessed 2009 Jul 18]
28. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70: 41-55
29. Controlled Substances Act (CSA). Title II of the Comprehensive Drug Abuse Prevention and Control Act of 1970, 21 U.S.C. Section 802 (1996) [online]. Available from URL: http://www.justice.gov/dea/pubs/csa.html [Accessed 2009 Jun 22]
30. RTI International. SUDAAN user-s manual: release 10.0. Research Triangle Park (NC): RTI International, 2008
31. Dorfman N. Attention grabbers: the ADHD market. Medical Marketing and Media. 2006 [online]. Available from URL: http://www.mmm-online.com/Attention- Grabbers/article/110398/ [Accessed 2009 Sep 1]
32. Tourangeau R. Cognitive sciences and survey methods. In: Jabine TB, Straf ML, Tanur JM, et al., editors. Cognitive aspects of survey methodology: building a bridge between disciplines. Washington, DC: National Academy Press, 1984: 73-100
33. Turner CF, Lessler JT, Gfroerer JC, et al. Survey measurement of drug use: methodological studies. Rockville (MD): National Institute on Drug Abuse, 1992. DHHS publication no. ADM 92-1929
34. US Department of Health and Human Services. Labeling revision for Concerta. Rockville (MD): US FDA, 2008 Jun 27 [online]. Available from URL: http://www.accessdata. fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction= Search. Search-Drug-Name [Accessed 2009 Jul 16]
35. Swanson JM, Wigal SB, Wigal T, et al. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study). Pediatrics 2004 Mar; 113 (3 Pt 1): e206-16
36. Cone EJ. Ephemeral profiles of prescription drug and formulation tampering: evolving pseudoscience on the Internet. Drug Alcohol Depend 2006 Jun; 83 Suppl. 1: S31-9
37. Bright GM. Abuse of medications employed for the treatment of ADHD: results from a large-scale community survey. Medscape J Med 2008 May 7; 10 (5): 111
38. Greenhill LL, Pliszka S, Dulcan MK, et al. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 2002 Feb; 41 (2 Suppl.): 26-49S
39. Birnbaum HG, Kessler RC, Lowe SW, et al. Costs of attention deficit-hyperactivity disorder (ADHD) in the US: excess costs of persons with ADHD and their family members in 2000. Curr Med Res Opin 2005 Feb; 21 (2): 195-206